BioMedNewsBreaks

FridayMay 17, 2019 1:14 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Taking Unique Gene Therapy Approach to Cancer Treatment

Genprex (NASDAQ: GNPX) is a clinical-stage, gene-therapy company focused on the advancement of its lead drug candidate, Oncoprex(TM) immunogene therapy. Oncoprex is an investigational therapy for non-small cell lung cancer (“NSCLC”). An article discussing the company reads, “Oncoprex is designed to interrupt cell signaling pathways that cause replication and proliferation of cancer cells, to target and kill cancer cells via receptor pathways, and to stimulate natural immune responses against cancer. Oncoprex consists of the TUSC2 tumor suppressor gene encapsulated in a positively charged lipid nanoparticle. It is injected intravenously, specifically targeting cancer cells, which generally have a negative electrical charge.…

Continue Reading

WednesdayMay 08, 2019 10:11 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Retains Pharmaceutical Branding Agency to Oversee Lead Drug Candidate Naming Process

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) this morning announced that it has retained the services of leading pharmaceutical branding agency, Addison Whitney, representing the next step toward commercialization of its lead drug candidate. Utilizing its 28-year history, Addison Whitney will oversee the proprietary and non-proprietary drug naming process for the company’s drug candidate for non-small cell lung cancer, presently known as Oncoprex(TM) immunogene therapy. “Retaining Addison Whitney is an important step in bringing our drug candidate to market,” Genprex Chairman and CEO Rodney Varner stated in the news release. “Obtaining regulatory approval of proprietary and non-proprietary drug names is a…

Continue Reading

ThursdayMay 02, 2019 3:14 pm

BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data in Lung Cancer Treatment Study

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) recently reported that positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody was recorded by its University of Texas MD Anderson Cancer Center collaborators in a lung cancer treatment study (http://nnw.fm/8E4bC). An article discussing the study reads, “The results of the study, which analyzed the combination of the TUSC2 gene and anti-PD1 antibody pembrolizumab, were presented in a poster at the 2019 American Association of Cancer Research Meeting. TUCS2 is a tumor suppressor gene and the active agent in Genprex’s Oncoprex immunogene therapy. . . . The poster data showed…

Continue Reading

MondayApr 22, 2019 3:40 pm

BioMedNewsBreaks – Why Genprex Inc. (NASDAQ: GNPX) Is ‘One to Watch’

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) is focused on the development of potentially life-changing technologies for cancer patients. A recent article discussing GNPX reads, “Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer. . . . Genprex’s initial product candidate is Oncoprex, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways…

Continue Reading

MondayApr 15, 2019 2:04 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) at Forefront to Advance Innovative Developments in Fight Against Lung Cancers

Clinical-stage gene-therapy company Genprex (NASDAQ: GNPX) is at the forefront to advance innovative developments in the war against lung cancers, testing its trademarked Oncoprex immunogene therapy. A recent article discussing this reads, “Oncoprex’s phase I and II clinical-stage trial therapies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities (http://nnw.fm/aJtE9). The company has a portfolio of 30 issued patents and two more pending, and it is also conducting preclinical research to…

Continue Reading

MondayApr 08, 2019 11:46 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data at 2019 AACR Annual Meeting

Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning announced that its collaborators from the University of Texas MD Anderson Cancer Center (“MD Anderson”) detailed positive preclinical data, in a poster presented at the American Association of Cancer Research Meeting 2019, regarding the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer. TUSC2 is a tumor suppressor gene and the active agent in Genprex’s Oncoprex immunogene therapy. “Development of an improved humanized patient-derived xenograft, Hu-PDX, mouse model for evaluation of antitumor immune response in lung cancer,” was the title of the poster,…

Continue Reading

TuesdayApr 02, 2019 9:53 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Posts Clinical, Corporate and Financial Update

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Monday provided a clinical, corporate and financial update for the year ended December 31, 2018. Among other highlights, Genprex reached various milestones in 2018 and early 2019 which included completing its initial public offering (“IPO”) and listing of common stock on NASDAQ Capital Market, completing a $10 million private placement, and securing a contract with Accenture to provide clinical data management services to help fast-track the clinical development of Oncoprex(TM). “Over the past year, we made great progress in advancing the development of our gene therapy platform, including Oncoprex(TM) immunogene therapy for…

Continue Reading

ThursdayMar 14, 2019 11:53 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Present at Seventh Annual ARM Cell & Gene Therapy Investor Day in New York City

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it will be presenting at the upcoming ARM Cell & Gene Therapy Investor Day, hosted by the Alliance for Regenerative Medicine, to be held in New York City on March 21, 2019. Unique to the medical and biotech communities, the investor conference focuses on fast-paced, concise presentations from more than 35 companies, consolidated to a one-day conference while allowing opportunities for one-on-one partnering with venture and strategic investors. Genprex’s presentation is scheduled for Thursday, March 21, at 2:30-2:45 p.m. EDT in the Main Bar Room of the Metropolitan Club,…

Continue Reading

ThursdayMar 07, 2019 9:34 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Names New Additions to Senior Team

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) announced on February 27 that it has hired Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing. The move to grow the company’s senior team is in accordance with Genprex’s preparation to expand its operations and focus on corporate communications in 2019. Chapdelaine will be tasked with overseeing analytical development, chemistry, manufacturing and controls, technical operations and supply chain management for the company. Dabbs will oversee the development and implementation of internal and external communication and marketing plans as well as managing the company’s…

Continue Reading